Am J Clin Nutr-2008-Pearce-638-44

合集下载

人工合成色素安全吗?

人工合成色素安全吗?

人工合成色素安全吗?在长期以来为人工食品色素的安全性进行坚定辩护后,联邦政府首度就诸如吉露果子冻,Lucky Charms麦片,Minute Maid柠檬水等食品是否应就鲜艳的人工色素与部分儿童的行为异常恶化(如多动症)之间的联系加以警示进行公开讨论。

美国食品与药品管理局(FDA)在很久之前就下有结论:在人工食品色素和行为异常或其他健康问题之间没有明显联系,该局在这一问题上的看法在近期也不可能改变。

但是在周三和周四,FDA会请专家组围绕可能带来政策变化的一些证据和建议进行商讨,其中包括在食品包装上增加警示标签。

越来越多的研究显示,在人工色素和儿童行为异常之间的确存在联系,这至少已引起监管当局的注意,特别为此举行听证。

这对牵涉其中的消费者权益团体来说也是一个胜利。

在一份总结报告中,FDA的一众科学家指出,尽管正常儿童不会受染色剂影响,但有行为问题的儿童会因为接触众多食品中的添加剂——包括但不仅限于人工合成色素——而使情况恶化。

作为两位孩子的母亲,来自纽约州詹姆斯敦的勒妮·仙特(Renee Shutters)在周二的电话采访中表示,两年前她5岁的儿子特顿(Trenton)在学校有严重的行为问题,直至她将儿子饮食中含有人工色素的食品去除。

“我确认无疑,问题的根源在于人工合成色素,因为很简单,你可以象控制开关一样去进行验证。

”仙特女士说。

但是劳伦斯·迪勒(Lawrence Diller)医生,来自加州核桃溪市的行为问题儿科医师表示,有关“饮食在多数儿童的行为异常问题上扮演了举足轻重的角色”这一说法基本上是空穴来风。

“这纯粹是无法禁绝的坊间传说,”迪勒医生说。

在天然食品色素的安全问题上不存在争论,食品生产商长期以来都在为人工色素的安全性进行辩护。

在一份声明中,美国食品饮料和消费品制造商协会(GMA)宣称“全球范围内的主要安全机构检视了可以查到的所有科学文献,并得出结论:在人工色素和儿童多动症之间没有明显的联系。

急性胰腺炎的营养管理

急性胰腺炎的营养管理
or
formula enteral
polymeric
in
formula:is
acute
there

better choice for Randomized Enteral
Nutr,
nutrition
panereatitis? J Parenter
Nutritional
营养疗法;细菌移位;
of Acute
胃肠道;肠内营养
DOU Xiaotan,ZOU Xiaoping.Department
Management
Pancreatitis
Hospital
of Gastroenterology,Naming
Drum Tower Hospital,The
在营养耐受性、总感染发生率、死亡率方面均未显示
感染性坏形液体积聚、呼吸衰竭发生率较48
h后
EN组(100例)均有显著改善(P值均<0.05);研究 还发现EN起始时间是感染性坏死/液体积聚的独 立危险因素(OR=4.09;P=0.028)。但EN也绝非
越早越好。Petrov等"o以24 h作为临界点,对4项 I临床随机对照试验(RCT)行meta分析发现,对评估 为SAP的患者,24 h内给予营养治疗,无论是EN还 是PN,其多脏器功能衰竭(RR=0.43)、死亡率(RR =0.51)、胰腺脓肿发生率(RR=0.65)均有所增
consumption
severe
acute
pancreatitis,has high mortality.Digestive system is seriously of imbalance between
in
injured and

(精选)近10年瘤胃微生物分离培养研究进展

(精选)近10年瘤胃微生物分离培养研究进展
瘤胃中细菌参与大部分营养物质的降解和生成,可降解 纤维、半纤维素、淀粉、蛋白质和脂类物质等,产生 VFA、琥珀 酸、乳酸、氨基酸、氨和脂肪酸等。近 10 年,国内外新分离的 细菌包括纤维/半纤维素降解菌和淀粉分解菌有 3 个属和 6 个种,蛋白质降解菌有 2 个属和 1 个种,脂类分解菌 1 个种, 乳酸产生菌 1 个属 2 个种,琥珀酸产生菌 1 个种,丁酸产生菌 2 个种,植酸酶产生菌 1 个种,吲哚形成菌 1 个种和耐地衣酸 菌 1 个种,见表 1。这些菌株在分类地位上属于新的种或属, 有些是首次从瘤胃中分类获得,呈现出一些新的菌株形态和 发酵特征。另外,近十年国内外研究者分离获得瘤胃新菌株 大约 39 种,这不仅补充了细菌菌种资源库,而且提供了新的 微生物形态和发酵特征。但对于瘤胃细菌的分离纯培养,大 部分学者仍侧重于瘤胃新纤维类降解菌的分离,可能与受关 注度越来越高的生物能源有关。 3 瘤胃古菌
China)
【Abstract】 The research of rumen microbiology is the key of ruminant nutrition. A large number of microorganisms par-
ticipating in nutritional metabolism have been isolated from rumen since the middle of 20th century. Nowadays,although it is
more and more popular to use molecular biological methods in the study of rumen microorganisms,traditional methods still play

急性胰腺炎的营养管理

急性胰腺炎的营养管理

急性胰腺炎的营养管理窦晓坛;邹晓平【摘要】急性胰腺炎尤其是重症急性胰腺炎病情凶险,死亡率高.胰腺炎时,消化系统受累严重而能量消耗增加,供需矛盾突出,禁食导致的继发性肠道细菌易位更加重了患者的死亡率.对急性胰腺炎患者进行营养管理不仅关系到营养本身的问题,更是对减少并发症、改善患者预后产生重要的影响.从传统的“胰腺休息”理论到目前主张的积极早期“胃肠激活”理论,营养问题在急性胰腺炎病理生理过程中所起的作用逐渐清晰.【期刊名称】《胃肠病学》【年(卷),期】2014(019)006【总页数】3页(P321-323)【关键词】胰腺炎;营养疗法;细菌移位;胃肠道;肠内营养【作者】窦晓坛;邹晓平【作者单位】南京大学医学院附属鼓楼医院消化科 210008;南京大学医学院附属鼓楼医院消化科 210008【正文语种】中文急性胰腺炎(acute pancreatitis, AP)尤其是重症急性胰腺炎(severe acute pancreatitis, SAP)病情凶险,死亡率高,营养问题在胰腺炎整个发病过程中始终不能回避。

在很长一段时期,胰腺炎营养管理以“胰腺休息”为理论基础[1],以不刺激胰腺外分泌为核心,包括长时间禁食、肠外营养(parenteral nutrition, PN)、短肽要素饮食、循序渐进恢复进食(流质-半流质-软饭-普食)、放置鼻-空肠营养管等一系列避免刺激胰腺外分泌的措施。

然而随着研究的深入,颠覆性的研究结论不断出现:这些措施有的没有必要,加重患者经济负担;有的起了反作用,给患者带来了危害。

“胰腺休息”理论不断受到质疑和挑战。

一、肠内营养(enteral nutrition, EN):加重胃肠道负担?通常认为AP早期胃肠道功能受累,此时进食可加重患者腹部症状(腹痛、腹胀),结合胰腺休息理论,PN一度成为AP患者的营养首选:既可避开食物刺激导致的胰腺分泌,又可使受累的胃肠道得到休息。

然而数十年来大量研究证实,EN较PN能显著减少患者胰腺感染并发症的发生,降低死亡率[2-4]。

Crafter’s Choice Cucumber Mint 香精油 说明书

Crafter’s Choice Cucumber Mint 香精油 说明书

Product: Crafter’s Choice™ Cucumber Mint Fragrance Oil7820 E Pleasant Valley RdIndependence, OH 44131(800) 359-0944 Page 1 of 3 2023-04-04 IndiMade Brands, LLC certifies that the above-mentioned fragrance product is in compliance with the standards of the International Fragrance Association [IFRA 50th Amendment (June '21)], provided the fragrance is used in the following application(s) at the following maximum concentration level(s):Product: Crafter’s Choice™ Cucumber Mint Fragrance Oil7820 E Pleasant Valley RdIndependence, OH 44131(800) 359-0944 Page 2 of 3 2023-04-04Product: Crafter’s Choice™ Cucumber Mint Fragrance Oil7820 E Pleasant Valley RdIndependence, OH 44131(800) 359-0944 Page 3 of 3 2023-04-04For all other applications, or use at higher concentration levels, a new evaluation will be required.The IFRA standards regarding use restrictions are based on safety assessments by the Research Institute for Fragrance Materials (RIFM) Expert Panel (REXPAN) and are enforced by the IFRA Scientific Committee. Evaluation of individual fragrance materials is made according to the safety standards contained in the relevant section of the IFRA Code of Practice.It is the ultimate responsibility of the customer to ensure the safety of the final product containing this fragrance, by further testing, if necessary.The above-mentioned fragrance product contains ingredients which are NOT considered GRAS, Generally Regarded as Safe as a Flavor Ingredient.。

辣椒英文文献已读

辣椒英文文献已读

2001年,C. Djian-Caporalino · L.Pijarowski · A. Fazari M. Samson · L.Gaveau · C.O’Byrne · V. Lefebvre C. Caranta · A. Palloix · P. Abad发表文章High-resolution genetic mapping of the pepper (Capsicum annuumL.)resistance loci Me3 and Me4 conferring heat-stable resistance to root-knot nematodes (Meloidogyne spp.)采用从C. annuum F1代得到的双单倍体(DH)群体构建了两张种内图谱,主要采用AFLP 和RAPD标记。

图谱长度1,582 cM ,共227 标记,18个连锁群,覆盖了67%的辣椒基因。

本研究采用的材料是C. annuum parents ‘Yolo Wonder’(‘YW’) and‘PM687’。

抗性品系PM687来源于印度,从PI322719群体中获得,YW是一个感病品种,Me3和Me4都是抗根结线虫基因。

PM687和YW杂交F1代有103个单双倍体(DH),163株F2代个体,‘Perennial’, another inbred line of C. annuum (see Table 1)used to generate the DH200 pepper map,另外一个亲本。

采用RAPD和AFLP标记,分析产生了与Me3连锁的8个相斥性标记和4个相引性标记。

在基因两边最近的距离是0.5,1.0,1.5和3cm,Me4与Me3相距100cm,Me3最近的基因名为Q04-0.3,距RAPD标记10.1cm,名为CT135d的距RFLP标记2.7cm.。

异麦芽酮糖的低血糖指数特性及健康功能

异麦芽酮糖的低血糖指数特性及健康功能

性 [7] ꎮ 鉴于亚洲人群乳糖不耐受症的高发率ꎬ 异麦芽
龋齿形成ꎬ 因为它可抵抗人体口腔微生物的酵解反应ꎻ
吸收ꎬ 血糖指数低ꎮ 这种特性使得异麦芽酮糖独一无
在酸性条件下稳定存在ꎻ 在小肠中缓慢消化、 持续地
二ꎬ 因为其他种类的低血糖指数碳水化合物实际上是
释放能量ꎻ 具有低血糖指数和低胰岛素反应特性ꎻ 促
相比ꎬ 餐后摄入异麦芽酮糖可产生更高的 GLP ̄1 肠促胰
岛素反应、 更低的 GIP 反应以及更低的血糖和胰岛素反
应[11] ꎮ 同样ꎬ 由德国人体营养研究所临床营养系主任
Andreas Pfeiffer 教授进行的一项人体临床研究证实ꎬ 与
蔗糖相比ꎬ 异麦芽酮糖能降低糖尿病患者的血糖和胰岛
素反应ꎬ 并降低 GIPꎬ 同时增加 GLP ̄1 分泌[9] ꎮ 由于异
高血糖指数碳水化合物不同ꎬ 这会产生一个低血糖反
应ꎬ 但没有明显下降[2] ꎮ 健康成年人的血糖反应较低ꎬ
相应地ꎬ 与胰岛素的释放较低有关 (图 1)ꎮ 来自 30 多
项人体临床试验的全部证据一致表明ꎬ 与其他参考碳水
化合物 (包括蔗糖和麦芽糊精) 相比ꎬ 异麦芽酮糖的餐
后血糖和胰岛素反应更低 (图 2)ꎮ 这些试验是在 250 多
ꎮ 异麦芽酮糖促进脂肪氧化的
蔗糖的研究中得到了证实[35] ꎮ 一项随机、 双盲对照研
[2]
超重和肥胖的成年人、 糖尿病患者以及训练有素的运动
员身上都有体现
部脂肪含量越高ꎬ 患糖尿病的风险就越大[16ꎬ33] ꎮ
ꎬ 这在健康人群、
特的碳水化合物ꎬ 可促进脂肪氧化
低血糖指数特性有助于人体摄入低血糖指数饮食获得更
健康的血糖水平ꎮ 一项采用 24h 连续血糖监测系统对健

胰腺炎营养治疗的国际共识指南

胰腺炎营养治疗的国际共识指南

胰腺炎营养治疗国际共识指南International Consensus Guidelines for Nutrition Therapy in PancreatitisIndication for Nutrition Therapy营养治疗的适应症1.Pancreatitis patients are at nutrition risk and should be screened. (Grade B: Gold)1.胰腺炎患者进行营养治疗的风险应进行评估筛选。

(B级:黄金)2. For mild to moderate disease, analgesics, intravenous(IV) fluids, and nil per os (NPO) with a gradual advancement to diet (usually within 3–4 days) are recommended. (Grade C: Silver) 2.轻度至中度AP,建议给予止痛药,静脉输液,禁食并逐步进食(通常在3-4天内完成过度). (C级:银)The need for nutrition therapy (NT) by the enteral or parenteral route should be based on the extent of disease and nutrition status of the patient.肠内或肠外途径营养治疗(NT)需要根据病人疾病和营养状况的程度决定。

3. NT is not generally needed for mild to moderate disease unless complications ensue. (Grade A: Platinum)3.轻度至中度的AP一般不需要NT,除非发生并发症. (A级:白金)4. NT should be considered in any patient regardless of disease severity if the anticipated duration of being NPO is >5–7 days. (Grade B: Gold)4.任何患者如果预期禁食时间大于5-7天,不论病情严重程度都应考虑NT(B级:黄金)5. NT is needed in mild to moderate disease when the patient has been NPO for 5–7 days. (Grade B: Gold)5.轻度到中度AP患者禁食5-7天需要NT(B级:黄金)6. Early NT is indicated for severe pancreatitis. (Grade A: Platinum)6.重症胰腺炎需早期NT (A级:白金)7. NT is useful in the management of patients who develop complications of surgery. (Grade B: Gold)7.有手术并发症的病人NT非常有用. (B级:黄金)Use of Enteral Nutrition肠内营养的使用8. Enteral nutrition (EN) is generally preferred over parenteral nutrition (PN), or at least EN should, if feasible, be initiated first. (Grade A: Platinum)8.肠内营养(EN)一般优于肠外营养(PN),如果EN可行应作为首选. (A级:白金)9. EN may be used in the presence of pancreatic complications such as fistulas, ascites, and pseudocysts.(Grade C: Silver)9. EN也可用于发生胰腺并发症者如瘘,腹水,假性胰腺囊肿(C级:银)10. Continuous EN infusion is preferred over cyclic or bolus administration. (Grade B: Gold)10. EN采用连续性输入方法优于周期性定时输入或推注的给予方法. (B级:黄金)11. Nasogastric tubes may be used for administration of EN. Postpyloric placement is not necessarily required. (Grade B: Gold)11.鼻胃管也可用于EN的输入,不一定要越过幽门后放置鼻空肠管(B级:黄金)12. For EN, consider a small peptide-based mediumchain triglyceride (MCT) oil formula to improve tolerance. (Grade B: Gold)12.对于EN,考虑以小肽为基础的含中链脂肪酸(MCT)的配方以提高耐受性. (B级:黄金)Use of Parenteral Nutrition肠外营养的使用13. Use PN if NT is indicated, when EN is contraindicated or not well tolerated. (Grade A: Platinum)13.如果需要NT,当禁忌行EN或不耐受时使用PN. (A级:白金)14. IV fat emulsions are generally safe and well tolerated as long as baseline triglycerides are below 400mg/dL (4.4 mmol/L) and there is no previous history of hyperlipidemia. (Grade B: Gold)14.只要甘油三酯低于400毫克/分升(4.4毫摩尔/升)和既往无高脂血症历史的患者静注脂肪乳剂通常是安全的(B级:黄金)15. Glucose is the preferred carbohydrate source with metabolic control of glucose as close to normal as possible. (Grade C: Silver)15.葡萄糖是的首选碳水化合物来源,糖代谢尽可能控制接近正常. (C级:银)16. Consider use of glutamine (0.30 g/kg Ala-Gln dipeptide).(Grade C: Silver)16.谷氨酰胺可以考虑使用(ALA-谷氨酰胺肽0.30克/公斤).(C级:银)17. No specific complications of PN are unique to patients with pancreatitis. In general, avoid overfeeding.(Grade C: Silver)17.胰腺炎患者行PN没有特殊并发症,一般情况下避免过度营养(C级:银).Both Enteral and Parenteral Nutrition肠内和肠外营养18. Meet macronutrient requirements with NT. (Grade B: Gold)a. Calories: 25–35 kcal/kg/db. Protein: 1.2–1.5 g/kg/d18. NT营养素要求满足(B级:黄金):a.卡路里:25-35千卡/公斤/天;b.蛋白质:1.2-1.5克/公斤/天胰腺炎营养治疗的国际共识指南营养治疗的适应症1.胰腺炎患者进行营养治疗的风险应进行评估筛选。

  1. 1、下载文档前请自行甄别文档内容的完整性,平台不提供额外的编辑、内容补充、找答案等附加服务。
  2. 2、"仅部分预览"的文档,不可在线预览部分如存在完整性等问题,可反馈申请退款(可完整预览的文档不适用该条件!)。
  3. 3、如文档侵犯您的权益,请联系客服反馈,我们会尽快为您处理(人工客服工作时间:9:00-18:30)。

Effect of carbohydrate distribution on postprandial glucose peaks with the use of continuous glucose monitoring in type2diabetes1–3 Karma L Pearce,Manny Noakes,Jennifer Keogh,and Peter M CliftonABSTRACTBackground:Large postprandial glucose peaks are associated with increased risk of diabetic complications and cardiovascular disease. Objective:We investigated the effect of carbohydrate distribution on postprandial glucose peaks with continuous blood glucose mon-itoring(CGMS),when consuming a moderate carbohydrate diet in energy balance in subjects with type2diabetes.Design:Twenty-three subjects with type2diabetes were randomly assigned to each of four3-d interventions in a crossover design with a4-d washout period.Identical foods were provided for each treat-ment with a ratio of total carbohydrate to protein to fat of40%:34%: 26%but differing in carbohydrate content at each meal:even distri-bution(CARB-E;Ȃ70g carbohydrate),breakfast(CARB-B),lunch (CARB-L),and dinner(CARB-D),each providingȂ125g carbohy-drate in the loaded meal in a9-MJ diet.Glucose concentrations were continuously measured with CGMS.Outcomes were assessed by postprandial peak glucose(Gmax),time spent 12mmol/L(T 12),and total area under the glucose curve(AUC20).Results:Daily Gmaxdiffered between treatments(P҃0.003)with CARB-L(14.2Ȁ1.0mmol/L),CARB-E(14.5Ȁ0.9mmol/L),and CARB-D(14.6Ȁ0.8mmol/L)being similar but lower thanCARB-B(16.5Ȁ0.8mmol/L).Meal Gmaxwas weakly related to carbohydrate amount and glycemic load(r҃0.40–0.44).T 12 differed between treatments(P҃0.014),and a treatment҂fasting blood glucose(FBG)interaction(P҃0.003)was observed with CARB-L(184Ȁ74min) CARB-B(190Ȁ49min) CARB-D(234Ȁ87min) CARB-E(262Ȁ91min).Total AUC20was not significantly different between treatments.After adjustment for FBG,treatment became significant(P҃0.006);CARB-L(10049Ȁ718mmol/L҂20h) CARB-E(10493Ȁ706mmol/L҂20h) CARB-B(10603Ȁ642mmol/L҂20h) CARB-D(10717Ȁ638 mmol/L҂20h).Conclusion:CARB-E did not optimize blood glucose control as assessed by postprandial peaks,whereas CARB-L provided the most favorable postprandial profile.Am J Clin Nutr2008;87: 638–44.KEY WORDS Type2diabetes,carbohydrate distribution, moderate carbohydrate diet,continuous glucose monitoring,energy balance,postprandial blood glucoseINTRODUCTIONMore than140million people worldwide have diabetes,pre-dominately type2,with the prevalence of type2diabetes ex-pected to double by the year2030(1).In these persons,cardio-vascular disease(CVD)is the leading cause of morbidity and mortality,responsible for50–80%of deaths(2);estimates of the risk of CVD vary from2-fold(3)to30-fold(4)compared with persons without diabetes.Although glycated hemoglobin(Hb A1C)is a standard assess-ment tool to assess glucose control in type2diabetes,postpran-dial glucose(PPG)peaks were implicated as a risk factor for microvascular and macrovascular complications(4).Endothelial dysfunction and activation of the coagulation cascade(5)are likely to be initial steps involved in producing carotid thickening (5)and atherosclerosis(6).Although the European Diabetes Policy group has set maxi-mum PPG targets not to exceed either135mg/dL(7.5mmol/L) to reduce the arterial risk and160mg/dL(9.0mmol/L)to reduce microvascular risk(7),the American Diabetes Association (ADA)does not provide such targets,preferring to encourage persons with type2diabetes to maintain“blood glucose levels in the normal range or as close to normal as is safely possible”(8). The ADA does state that an understanding of the relation be-tween CVD events and treatments focused at explicitly lowering PPG is critical to reduce mortality as a consequence of CVD(9). Most studies confirm that the total carbohydrate intake from either a snack or a meal is a consistent predictor of PPG concen-trations(10).This has been observed in both single-meal(11)and mixed-meal studies(10).In2002,the ADA recommended that the carbohydrate and monosaturated fat together should provide 60–70%of energy intake(8),and moderate-carbohydrate diets are gaining popularity.Because of the difficulties in shifting large amounts of carbohydrate between meals,we used a moderate-carbohydrate,higher protein,energy-balanced diet (40%carbohydrate,34%protein,26%fat)to enable the greatest variation in carbohydrate distribution to be achieved.Studies that used moderate-carbohydrate interventions,comparing isoca-loric exchange of carbohydrate with protein,were shown to in-crease weight loss(12)and fat loss(12);to spare lean mass(13); 1From the Commonwealth Scientific and Industrial Research Organiza-tion(CSIRO),Health Sciences and Nutrition,Adelaide,South Australia, Australia(KLP,MN,JK,and PMC),and Department of Physiology,Uni-versity of Adelaide,Adelaide,South Australia,Australia(KLP).2Supported by a PhD scholarship from the Commonwealth Scientific and Industrial Research Organization,Health Sciences and Nutrition(KLP),and from the Department of Physiology,University of Adelaide(KLP).3Reprints not available.Address correspondence to KL Pearce,CSIRO Human Nutrition,PO Box10041,Adelaide BC,Australia.E-mail: karma.pearce@csiro.au.Received August27,2007.Accepted for publication October2,2007.638Am J Clin Nutr2008;87:638–44.Printed in USA.©2008American Society for Nutrition at Xinjiang Medical University on March 3, Downloaded fromto achieve better glycemic control (13)and insulin sensitivity (12);to reduce Hb A 1C values (14);and to improve the blood lipid profile (12).Dietary factors other than carbohydrate amount can affect blood glucose concentrations,eg,dietary fiber (15)and glycemic index (GI)(8).The consumption of protein (16)and fat (17),preprandial glucose concentrations (18),the degree of in-sulin resistance (19),and second meal effects (20)may also modify the effect of dietary carbohydrate on PPG concentrations.In addition,this study targeted persons with poorly controlled glycemia as a higher risk group for diabetic complications and effective clinical intervention.It was also anticipated that they would be more responsive to carbohydrate variability across the day.Although persons with type 2diabetes are often advised to evenly distribute daily carbohydrate intake over meals and snacks to blunt PPG peaks (21),no studies support whether this approach provides optimal glucose control.The relation between meal frequency and energy distribution but not carbohydrate distribution per se was examined in several small studies (n ҃6–120)(22–24).Beebe et al (24)showed that meal frequency did not alter fasting glucose or glucose tolerance,whereas Jenkins et al (22)and Bertelsten et al (23)have shown that an increase in meal frequency and a decrease in meal size lowered PPG con-centrations.No studies have examined the role of carbohydrate distribution at meals on daily PPG profiles.Our aim was to comprehensively assess diurnal glucose pro-files in free-living persons with type 2diabetes,when carbohy-drate distribution at meals is variably distributed,but total car-bohydrate remains the same.Our use of a continuous blood glucose monitoring system (CGMS)enables a noninvasive ap-proach to measuring PPG responses.We used an isocaloric moderate-carbohydrate,higher protein,energy-balanced diet (40%carbohydrate,34%protein,26%fat)consumed as 3meals for each of 4intervention periods.We hypothesized that an even distribution of carbohydrates may be an optimum pattern com-pared with 3other carbohydrate distribution interventions for attenuating PPG excursions.SUBJECTS AND METHODSSubjectsTwenty-four white men (n ҃8)and women (n ҃16)with type 2diabetes,aged 30–75y,with Hb A 1C values ͧ6.5%were recruited by public advertisement.Subjects were excluded if they had a malignancy;a history of liver,kidney,or gastrointes-tinal disease;or were unable to comply with study requirements.All experimental procedures were approved by the human ethics committees of the Commonwealth Scientific Industrial Research Organisation and the University of Adelaide,and all subjects provided written informed consent.Of the 24subjects,11managed their diabetes by diet,11required oral hypoglycemic medication [4with metformin (500mg/d to 3g/d)and gliclazide (1normal 160mg/d and 3slow release 30–60mg/d),1with metformin (2g/d)alone,1gliclazide 60mg/d alone,3with thiazolidinediones (rosiglitazone 8mg,pioglitazone 30–45mg)and metformin (1.5–2g/d),2with glimepiride (1–3mg)and metformin (500mg/d to 3g/d)],and 2required insulin (1with Humalog 30U and Protaphane 30U,the other with Protaphane 28U,gliclazide 90mg,and metformin 850mg).Other medications included antidepressants,antihyperten-sives,and lipid-lowering medication.Subjects were asked to maintain their usual daily activities and a constant dose and timing of their medication for the duration of the study.Baseline characteristics are shown in Table 1.MeasurementsCGMS is a well-recognized tool currently used by health pro-fessionals in type 1diabetes to identify timing and causes of hypoglycemia and hyperglycemic spikes with accuracy similar to that of self-monitoring of blood glucose (SMBG)(25).A Medtronic MiniMed CGMS (Northridge,CA)was used to obtain continuous glucose readings (26).Briefly,it consists of 4com-ponents:a sterile,single use glucose oxidase–based electrode sensor system inserted into interstitial fluid,a pager-sized elec-tronic monitor that records and stores data from the sensor,a cable that connects both the monitor and the sensor,and a com-munication station (Com-Station)that aids in the downloading of data to a personal computer (MEDTRONIC MINIMED software 3.0C program).A senserter,a spring-loaded device,was used to implant the sensor.The sensor obtained a glucose measurement of the extracellular glucose in the range of 2.2–22mmol/L (40–400mg/dL)every 10s,and the monitor stored a smoothed and filtered average of these values in its memory every 5min,yielding 288readings/d.This information was not revealed to the wearer.CGMS values 2.2mmol/L or 22mmol/L were recorded as 2.2or 22mmol/L.Fasting blood glucose (FBG)was recorded at 0530every morning during the 4d while wearing the CGMS monitor and averaged.The mean of the daily differences (MODD)is a term used to evaluate overall interday glycemic variation when CGMS values were used to evaluate blood glucose concentrations (27).This is the mean of the absolute value of the difference for 2individual blood glucose values initialized from the time of eating,on 2different days,during the 20-h time period.Resting blood pressure was measured by automated oscillom-etry (model 845XT/XT-IEC;Dinamap,Tampa,FL),with sub-jects in a seated position.Body height was measured to the nearest 0.1cm with the use of a stadiometer (SECA,Hamburg,Germany)with subjects barefoot in the free-standing position.Body weight was measured with subjects wearing light clothingTABLE 1Subject characteristics at baseline 1Male (n ҃7)Female (n ҃16)Total (n ҃23)Age (y)62.6Ȁ9.360.3Ȁ10.561.0Ȁ10.0Weight (kg)93.6Ȁ23.094.9Ȁ25.994.5Ȁ24.5BMI (kg/m 2)31.5Ȁ7.736.1Ȁ9.334.7Ȁ9.0Hb A 1C (%)8.3Ȁ1.48.5Ȁ1.78.6Ȁ1.6FBG (mmol/L)7.1Ȁ1.38.4Ȁ3.57.5Ȁ2.2SBP (mm Hg)131.8Ȁ14.4139.0Ȁ11.0136.6Ȁ12.3DBP (mm Hg)76.6Ȁ11.673.7Ȁ9.774.7Ȁ10.21All values are x ៮ȀSD.Age,systolic blood pressure (SBP),diastolic blood pressure (DBP),activity level,and glycated hemoglobin (Hb A 1c )were assessed at screening (2wk before commencing the study).Weight,BMI,and fasting blood glucose (FBG)concentrations were obtained at the week 0visit.For conversion from mmol/L to mg/dL for blood glucose concentrations,multiply by 17.86.Statistics were performed using a one-factor ANOVA.There were no significant difference between sexes.CARBOHYDRATE DISTRIBUTION AND TYPE 2DIABETES 639at Xinjiang Medical University on March 3, 2012Downloaded fromwith no shoes to the nearest 0.05kg,with the use of calibrated electronic digital scales (AMZ 14;Mercury,Tokyo,Japan).Daily activity levels were recorded,during each intervention,to 5%accuracy,with the use of a pedometer (model HJ-109,Omron Health Care,Tokyo,Japan).A venous blood sample was collected in a EDTA-coated tube for the measurement of Hb A 1C with the use of HPLC ion ex-change chromatography on a Bio-Rad VARIANT II [Hercules,CA;method certified by the National Glycohemoglobin Stan-dardization Program and secured to the Diabetes Control and Complication Trial (28)at the Institute of Medical and Veteri-nary Science (Adelaide,Australia)].DietThe study consisted of 4randomized diet treatments in which the ratio of carbohydrate to protein to fat was 40%:34%:26%(7%saturated fat,9%monounsaturated fat,9%polyunsaturated fat).Three-day physical activity diaries (29)were used in conjunction with the Schofield equation (30)to determine individualized energy requirements to maintain energy balance.All treatments contained identical foods and differed only in the way the foods were allocated at each meal (Table 2).For CARB-E,the carbo-hydrates were evenly distributed across the day (breakfast:70.7Ȁ2.3g;lunch:68.5Ȁ2.3g;dinner:68.2Ȁ2.2g);for CARB-B,the carbohydrates were loaded at breakfast (breakfast:128.4Ȁ4.2g;lunch:37.9Ȁ1.2g;dinner:38.3Ȁ1.3g);for CARB-L,the carbohydrates were loaded at lunch (breakfast:40.6Ȁ1.3g;lunch:125.4Ȁ4.1g;dinner:39.0Ȁ1.3g);and,for CARB-D,the carbohydrates were loaded at dinner (breakfast:44.1Ȁ1.4g;lunch:40.5Ȁ1.3g;dinner:122.7Ȁ0.4g).All foods were provided.Each 24-h treatment was repeated for 3consecutive days.The GI of the diet was calculated from international tables (31).GI data from persons with type 2diabetes were used when possible.The glycemic load (GL)of a typical serving of food was calculated as the product of the amount of available carbohydrate and the total GI of the food consumed at a given meal (32)(Table 2).Experimental designSubjects followed four,3-d treatment protocols in a random-ized crossover study design.Subjects attended the outpatients’clinic on a Monday afternoon.Subjects were weighed before the CGMS sensor was inserted subcutaneously into their abdominal wall or upper buttocks (a palm width below the waist)with the use of the senserter.The CGMS monitor was initialized and calibrated with the use of capillary SMBG measurements (Me-disense,Optimum;Abbott Laboratories,Abbott Park,IL)before leaving the clinic in accordance with the Medtronic Minimed operating instructions.The subjects consumed food of their choice for the remainder of the day (excluding alcohol)before fasting from 2000.The subjects calibrated the sensor 3additional times with the use of SMBG before retiring to bed.During the following 3consecutive days,subjects were asked to consume only the provided foods and to calibrate the sensor 4times daily (before breakfast,lunch,and dinner and at retiring)with the use of SMBG.Kitchen scales were provided (DZC 5000A;Procon Technology,Brisbane,Australia).Subjects were free to consume breakfast at anytime they wanted,provided that meals were consumed 6h apart.Each day they recorded the number of steps taken,the time of eating episodes,SGBM re-sults,and other matters that could potentially influence glucosevalues.Subjects also completed weighed food diaries that were analyzed with the use of FOODWORKS software (version 4;Xyris Software,Highgate Hill,Australia).The software is based on Australian Food Composition tables and food manufacturers’data.On Friday morning subjects returned to the clinic to be weighed,to have the CGMS sensor removed,and to have the data downloaded to the computer.Subjects were also interviewed about dietary compliance,activity levels,and adverse events.The process was repeated for 4consecutive weeks.Even though subjects were instructed to consume their meals 6h apart,the minimum length of time between meals was 5h.Accordingly,the 24-h CGMS trace was divided into 5-h intervals from the time of meal initiation for breakfast,lunch,and evening meals with a 5-h overnight slice beginning 5h after consuming the evening meal (fasting block),representing a total of 20h of blood glucose data during a 24-h period of monitoring.The 3d of monitoring produced 3҂20h of blood glucose data used in the analysis.Outcome was assessed by postprandial peak glu-cose (G max ),time spent 12mmol/L (T 12),and total area under the glucose curve (AUC 20).Statistical analysisAll data are presented as means ȀSEMs unless otherwise indicated.Statistical analysis was performed with the use of SPSS for WINDOWS 14.0software (SPSS Inc,Chicago,IL)with statistical significance set at an ␣level of P 0.05.Dietary compliance data were analyzed with the use of repeated-measures analysis of variance with sex as a between-subject factor.The total 20-h glucose AUC responses were calculated with the use of zero as a baseline,with the trapezoidal rule (33).In the initial analysis of AUC 20,G max ,and T 12,treatment was assessed with the use of a repeated-measures analysis of variance with the use of sex as a between-subject factor.In secondary analysis,FBG was included as a covariate and oral hypoglycemic medication as a factor.RESULTSSubjectsWith the exception of 1subject who failed to complete treat-ment CARB-L,24subjects completed at least 1d of the remain-ing treatments.Treatments CARB-E,CARB-B,CARB-L,and CARB-D were completed for 3full days by 21,22,19,and 24subjects,respectively.No adverse events were reported.Overall the minimum mean compliance to the dietary protocol across all 4treatments as assessed by energy intake was 96.9%Ȁ0.9%,and carbohydrate intake was 98.9%Ȁ0.9%with no sig-nificant difference between treatments or sex (n ҃23).The mean daily number of steps was 6117Ȁ469with no differences be-tween treatments.No weight change was observed between treatments (data not shown).Glycemic controlFBG concentrations did not differ significantly between days,by treatment,or by time (Figure 1).The MODD value was used to assess interday glycemic variation.The MODD value for treatment CARB-E varied between 1.3and 1.6mmol/L,repre-senting comparisons between days 1and 3,1and 2,and 2and 3.Similarly,the MODD value for treatments CARB-B,CARB-L,640PEARCE ET ALat Xinjiang Medical University on March 3, 2012Downloaded fromand CARB-D were 1.3–1.4mmol/L,0.0–1.2mmol/L,and 1.4–1.5mmol/L,respectively.Consequently,because no significant differences within treatment were observed (P 0.05),all avail-able data were used to produce a daily average.The lowest daily G max values were achieved for CARB-L (14.2Ȁ1.0mmol/L)followed by CARB-E (14.5Ȁ0.9mmol/L)and CARB-D (14.6Ȁ0.8mmol/L)with the highest value for CARB-B (16.5Ȁ0.8mmol/L).A significant difference was observed between treatments overall (P ҃0.003),with the dif-ference between CARB-B and CARB-E (P ҃0.018),CARB-Band CARB-L (P ҃0.002),and CARB-B and CARB-D (P ҃0.004)being significant.In T 12,treatment became significant (P ҃0.014)only after adjustment for FBG (P ҃0.003)with the lowest values for CARB-L (184Ȁ74min)and CARB-B (190Ȁ49min)and the highest values for CARB-D (234Ȁ87min)and CARB-E (262Ȁ91min).With the glucose AUC 20data,treatment alone had no effect,but it became significant after adjusting for FBG (P ҃0.006)(Figure 1E).AUC 20for CARB-L (10049Ȁ718mmol/L ҂20h)was lowest with CARB-E (10493Ȁ706mmol/L ҂TABLE 2Sample menu of foods and carbohydrate distribution during the day for an 8000-kJ diet 1CARB-ECARB-BCARB-L CARB-D ValueCarbohydrateValue CarbohydrateValue CarbohydrateValue CarbohydrateBreakfastMixed-grain bread (g)108461948243184318Polyunsaturated margarine (g)60408080Spreads (g)230230214060Fruit (g)3——1009————Ham (g)————10001000Reduced-fat cheese (g)4303——300303Skim milk (g)302——2001120011Total carbohydrate (g)52—94—30—32—Protein (g)21—22—38—35—Fat (g)10—9—12—12—GL 547—87—10—13—LunchMixed-grain bread (g)8637——151645018Polyunsaturated margarine (g)60——70120Spreads (g)2————281——Fruit (g)31001310012200258010Vegetables (g)6801801801801Ham (g)10001000————Tuna (g)——————1400Reduced-fat cheese (g)4——303————Skim milk (g)——23012————Total carbohydrate (g)51—28—91—29—Protein (g)25—35—16—36—Fat (g)10—9—10—15—GL 534—22—74—9—DinnerMixed-grain bread (g)——————10846Polyunsaturated blended oil (g)801006080Spreads (g)2——————341Fruit (g)32002210013100921023Vegetable (g)72186218621862186Skinless chicken (g)2800280028001200Diet yogurt (g)20011200112001120011Skim milk (g)20011——302302Total carbohydrate (g)50—30—28—89—Protein (g)81—74—75—53—Fat (g)24—26—22—19—GL 516—23—19—61—1CARB-E,carbohydrate was evenly distributed across the day;CARB-B,carbohydrate was loaded at the breakfast meal;CARB-L,carbohydrate was loaded at the lunch meal;CARB-D,carbohydrate was loaded at the evening meal;GL,glycemic load.2Low-joule spreads (diet jam,vegemite).3Apple,pear,or fruit salad.4Fat 65%.5Calculated as amount of carbohydrate (g)҂glycemic index (32).Glycemic index calculated from tables (31).6Lettuce and tomato.7Carrots,beans,or broccoli.CARBOHYDRATE DISTRIBUTION AND TYPE 2DIABETES641at Xinjiang Medical University on March 3, 2012Downloaded from20h),CARB-B (10603Ȁ642mmol/L ҂20h),and CARB-D (10717Ȁ638mmol/L ҂20h)differing from CARB-L by 4%,5%,and 6%,respectively.No statistical difference was observed between the CARB-E,CARB-B,CARB-L,and CARB-D treat-ments when mode of diabetes control (diet,insulin,or other diabetes medication)was included as a between-subject factor for AUC (P ҃0.497),G ma x (P ҃0.693),or T 12(P ҃0.068).Glycemic loadBecause the daily AUC 20did not differ significantly across the treatments,it did not matter how the total daily GL was divided across meals.However,this was not the case with T 12and G max ,because both T 12and G max differed significantly across treatments.In the loaded meals,daily G max was equivalent to meal G max .Meal G max was greatest with CARB-B because this had the greatest meal GL,but this was not true when comparing meal GL to CARB-D and CARB-L.Daily T 12did not cor-relate with daily GL.For all 276meals the correlation between carbohydrate amount and G max was 0.40;ie,carbohydrate amount accounted for only 16%of the variance in G max ,whereas the use of GL did not significantly improve the correlation (r ҃0.44).DISCUSSIONThe main findings of this study are that a more even distribu-tion of carbohydrates did not provide the most favorable total PPG profile.Lunchtime appeared to be the most favorable time to consume carbohydrates based on G max ,AUC 20,and T 12,but carbohydrate amount and GL at each meal was only weakly related to the G max of that meal,and they accounted for only 16–17%of the variance in G max .Data from several large epidemiologic (5,34,35)and inter-vention (36)studies in persons with type 2diabetes have empha-sized the importance of mealtime hyperglycemia as the predom-inant factor associated with increased risk of cardiovascular morbidity and mortality.Although G max was higher with CARB-B consistent with the higher GL,the G max was lower for CARB-L compared with CARB-D despite a higher GL in the former.When the T 12was examined,the lowest mean occurred with CARB-L followed closely by CARB-B,despite its higher peak values.When carbohydrates were loaded in the evening meal,CARB-D,a greater absolute amount of fat,protein,and meal volume at that meal might have led to a more delayed and sustained postprandial peak,the fat slowing the rate of gastric emptying (15),and the protein-induced insulin release may lower the peak (37).The lowest GL value for the loaded meal in CARB-D could not explain the highest T 12values for that arrangement.The highest value for the T 12occurred with CARB-E;in this arrangement the carbohydrate was evenly distributed across the 3meals,providing 3opportunities for sustained PPG output.Because persons with diabetes have excessive basal glucose pro-duction in the presence of fasting hyperinsulinemia (38)and defective suppression of endogenous glucose production (39),repeated exposure to a carbohydrate load is likely to maintain undesirable but consistently higher concentrations of glucose.Increasing evidence suggests that the postprandial state and indeed the hyperglycemic spikes are a contributing factor to atherosclerosis and the onset of cardiovascular complications.In persons with type 2diabetes,the Diabetes Intervention Study showed that PPG concentrations after breakfast was found to predict myocardial infarction and mortality in patientswithFIGURE 1.Diurnal glucose values.(A)Carbohydrate was evenly distributed across the day (n ҃21),(B)carbohydrate was loaded at the breakfast meal (n ҃22),(C)carbohydrate was loaded at the lunch meal (n ҃17),(D)carbohydrate was loaded at the evening meal (n ҃22).Each meal represents 5h of blood glucose monitoring.(E)CARB-E,carbohydrate was evenly distributed across the day;CARB-B,carbohydrate was loaded at the breakfast meal;CARB-L,carbohydrate was loaded at the lunch meal;CARB-D,carbohydrate was loaded at the evening meal (n ҃23for all treatments).For conversion from mmol/L to mg/dL for blood glucose concentrations,multiply by 17.86.Note that each graph represents 720individual blood glucose measurements;hence,it is not practical to present mean ȀSEM information.642PEARCE ET ALat Xinjiang Medical University on March 3, 2012Downloaded fromnewly diagnosed disease (40),whereas the San Luigi Gonzaga Diabetes Study showed the postprandial state after lunch pre-dicted the occurrence of cardiovascular events in a 5-yr follow-up study (41).Because glycemia reached after a 2-h post-glucose load as measured by the oral glucose tolerance test was shown to correlate with the postprandial state after a mixed meal (42),a body of evidence from the DECODE study,the Chicago Heart Study,the Hoorn Study,and the Honolulu Heart study [reviewed in Ceriello (43)]support a relation between increased postprandial glycemia and cardiovascular risk.Hence,strategies to minimize PPG concentrations are vital to reduce diabetic com-plications.Carbohydrate distribution had little influence on 20-h average glucose (AUC 20).However,when the data were examined fur-ther with the use of the average FBG as a covariate,CARB-L produced a more favorable profile,but the differences from the other treatments were small (4–6%).Overall,CARB-L resulted in lower AUC 20,G max ,and T 12values;this represented the most favorable time to eat carbohy-drate.On the basis of weight stability,dietary compliance,low but stable activity levels,the provision of all food,and the sim-ilarity between each day of the same treatment,the glucose changes that resulted from consuming the prescribed treatments were considered to be mainly attributed to the distribution of carbohydrates and not other confounding factors (15).Other observations included a trend toward a higher FBG value com-pared with premeal blood glucose values,with lower premeal glucose values throughout the day,as observed by others (10),with values returning to approximately the same values the fol-lowing morning,which is in part explained by circadian rhythm (44)(Figure 1).Although we expected to see some variability in interday gly-cemia because of subtle differences in timing of exercise,meals,and medication and poor health,the interday glycemic variation expressed as the MODD showed a maximum value of 1.6mmol/L across all 4treatments,essentially little difference in glycemic response across the 3treatment days.This variability is much smaller than the MODD value of 4.3mmol/L observed by others in subjects with type 2diabetes (27)and was due to the tight control and reproducibility of food consumption during the 3d in our study.Limitations to the study include variability in the data high-lighted by individual differences in maximum glucose response times to a carbohydrate load;the differences in lag times ob-served were up to 105min.This led to discrepancies observed between the maximum glucose concentrations calculated for G max compared with the maximum glucose values resulting from AUC 20.A possible explanation for this may be the highly vari-able rate of gastric emptying observed in subjects with type 2diabetes (45),the different action of medication in 11subjects (sulfonylureas that stimulate the pancreas to produce more insu-lin and biguanides that reduce the amount of glucose produced by the liver)(46),and the amount of glucose absorbed from food along with an insulin-sensitizing effect on muscle tissue through nonoxidative pathways (47).The strengths of this study include the use of CGMS as a noninvasive diurnal glucose monitoring tool in free-living per-sons.Without the use of the CGMS sensors,it would have been impossible to detect the dynamic changes in blood glucose con-centrations that cannot be detected with intermittent SMBG.The study diet composition of the main meals was similar to that of ahigher carbohydrate diet,which,in addition to 3main meals,incorporated higher carbohydrate snacks (48).The lower carbo-hydrate diet also enabled the greatest variation in carbohydrate distribution to be achieved.It was anticipated that persons with poorly controlled diabetes would be more responsive to carbo-hydrate variability across the day.Meal frequency and energy distribution were selected to reflect what many working persons with diabetes had reported in previous studies conducted by our group (data not published)and other groups (49).Exceptional compliance across all 4treatments we believe was in part due to the provision of all foods and the selection of commonly con-sumed items in the Australian diet.In addition,continuous glu-cose monitoring enabled a detailed glucose profile to be ob-tained.In conclusion,our results show for this acute study in persons with poorly controlled diabetes that on a 40%carbohydrate di-etary pattern even carbohydrate distribution is not optimal for minimizing PPG peaks.Minimizing carbohydrate at breakfast and shifting it to the lunch meal may provide lower diurnal glucose excursions (AUC 20,T 12,and G max ).Importantly,we consider these studies in support of concept rger chronic studies involving subjects of different nationalities would be required to determine the applicability of this approach to in the management of type 2diabetes.We thank the volunteers who made the study possible through their par-ticipation.We also thank Rosemary McArthur and Debbie Davies for their help in the nursing activities,Julia Weaver for assisting in the trial manage-ment,and Allen Gale for aiding in the recruitment.The author’s responsibilities were as follows—KLP,MN,and PMC:conceived of and designed the study and contributed to data analysis and manuscript writing;KLP,MN,PMC,and JK:contributed to designing the study dietary protocol;KLP:implemented the study including the dietary protocol,collected the data,and wrote the manuscript.None of the authors had a personal or financial conflict of interest.REFERENCES1.Diet,nutrition and the prevention of chronic diseases.World Health Organ Tech Rep Ser 2003;916:i–viii,1–149.2.Haffner SM,Lehto S,Ronnemaa T,Pyorala K,Laakso M.Mortality from coronary heart disease in subjects with type 2diabetes and in nondiabetic subjects with and without prior myocardial infarction.N Engl J Med 1998;339:229–34.3.Fox CS,Coady S,Sorlie PD,et al.Trends in cardiovascular complica-tions of diabetes.JAMA 2004;292:2495–9.4.Hu FB,Stampfer MJ,Solomon CG,et al.The impact of diabetes mellitus on mortality from all causes and coronary heart disease in women:20years of follow-up.Arch Intern Med 2001;161:1717–23.5.Bonora E.Postprandial peaks as a risk factor for cardiovascular disease:epidemiological perspectives.Int J Clin Pract Suppl 2002;129:5–11.6.Celermajer DS.Endothelial dysfunction:does it matter?Is it reversible?J Am Coll Cardiol 1997;30:325–33.7.Standl E.International Diabetes Federation European policy group stan-dards for diabetes.Endocr Pract 2002;8(supp 1):37–40.8.Franz MJ,Bantle JP,Beebe CA,et al.Evidence-based nutrition princi-ples and recommendations for the treatment and prevention of diabetes and related complications.Diabetes Care 2003;26(suppl):S51–61.9.American Diabetes Association.Postprandial blood glucose.Diabetes Care 2001;24:775–8.10.Gannon MC,Nuttall FQ,Westphal S,Fang S.Acute metabolic responseto high carbohydrate,high-starch meals compared with moderate-carbohydrate,low-starch meals in subjects with type 2diabetes.Diabe-tes Care 1998;21:1619–26.11.Sheard NF,Clark NG,Brand-Miller JC,et al.Dietary carbohydrate(amount and type)in the prevention and management of diabetes:a statement by the American Diabetes Association.Diabetes Care 2004;27:2266–71.CARBOHYDRATE DISTRIBUTION AND TYPE 2DIABETES 643at Xinjiang Medical University on March 3, 2012Downloaded from。

相关文档
最新文档